Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHRQ registry handbook

This article was originally published in The Gray Sheet

Executive Summary

The Agency for Healthcare Research & Quality releases "Registries for Evaluating Patient Outcomes: A User's Guide" May 16, supported with funding from CMS. The 219-page 1guide, which in large part mirrors a draft version released in October, compiles 23 registry case studies and 343 references, and involved 39 contributors from government, industry and academia (2"The Gray Sheet" Oct. 23, 2006, p. 9). The guide includes chapters on registry design, ethical issues and data ownership, adverse event detection and assessing registry quality...

You may also be interested in...



Increased Patient Registry Use Has Industry Looking For Direction

With registries set to become a more prevalent means of data collection - particularly under CMS' new coverage-with-evidence-development (CED) policy - industry is seeking guidance on how such studies can comply with patient privacy laws

Adalvo Hails First European Launch Of Prolonged-Release Pregabalin

After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel